Jan 08, 2024 / 05:45PM GMT
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
Thanks, everyone. If you can take a seat, we can start the next session here. I am Robbie Marcus, the med tech analyst at JPMorgan. Very happy to introduce Kevin Sayer, the CEO of DexCom. Kevin is going to do a presentation and then me and Jereme will join him on stage for some Q&A after.
Kevin Ronald Sayer - DexCom, Inc. - Executive Chairman, CEO & President
Thank you, Robbie. You know those who work with me often say I start our meetings by asking a very simple question, what problem are we trying to solve today? Well, diabetes is a big problem. With the estimated global population of people with diabetes growing from 150 million in the year 2000 to more than 500 million in year 2021 and approaching just under 800 million in the year 2045. This is a problem that's just not going away. And most of these people are still treated by fingersticks.
And it's not just the growth in the population that's staggering, it's the cost associated with their care. It costs the system
Dexcom Inc at JPMorgan Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers